Invivyd, Inc. (IVVD) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-05
How it makes money
It earns revenue by selling monoclonal antibody treatments for immunocompromised patients, with financial success contingent on the continued efficacy of its therapy against viral variants.
It provides medical treatments specifically for individuals who cannot generate a sufficient immune response from standard vaccinations. Revenue is generated from the sale of its authorized monoclonal antibody (mAb) therapy.
Profitability is highly variable because the product's authorization depends on the virus not evolving to a point where the treatment becomes ineffective against circulating strains.
What protects it: the moat
It claims protection through its intellectual property portfolio and proprietary experience in developing monoclonal antibody therapies, though these remain subject to significant competitive and regulatory risks.
The company relies on its research and development capabilities and intellectual property to differentiate its therapeutic candidates. It views its history in the viral space as a competitive barrier, though it acknowledges the need to constantly defend this position against rivals and evolving regulatory requirements.
Management asserts that its engineering processes for mAb therapies provide a distinct advantage, though no long-term economic moat is currently established.
What could damage it
The company faces permanent impairment if viral evolution renders its current and pipeline treatments ineffective, thereby stripping the business of its primary commercial purpose.
Because the product is designed for specific viral variants, a mutation in the virus that evades the company's antibody therapy would nullify its regulatory authorization. This would immediately eliminate its sole revenue stream and invalidate the logic of its current commercial and clinical pipeline, which is highly specialized for these specific virus-based indications.
About Invivyd, Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.